在人群中阿齐思罗米的显著预测因素 药动力学分析:系统性审查
Runcong Zhang1,2, Yuebin Fang3, Yinhui Wang1,2
1Department of Pharmacy, Changxing People's Hospital, Changxing, Zhejiang, People's Republic of China.
阿齐思罗米辛的剂量显示出可变性. 体重是关键,但年龄,肝功能,怀孕和种族对儿童和妇女的影响清除,需要个性化剂量调整以获得最佳治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物新陈代谢 药物新陈代谢
背景情况:
- 阿齐思罗米是细菌感染的重要抗生素,特别是儿科的Mycoplasma肺炎.
- 由于阿齐思罗米的药理动力学具有显著的个体间变异性,因此需要对共变量进行鉴定,以优化剂量.
研究的目的:
- 系统地审查和分析阿齐思罗米的种群药动力学研究.
- 为了确定影响不同患者群体中阿齐思罗米药理动学的显著共变量.
主要方法:
- 在PubMed,Embase和Web of Science数据库中的系统文献搜索,截至2024年5月30日.
- 提取和比较研究设计,特征和药理动力学模型参数.
- 分析时间度曲线和森林地块,以确定共变量.
主要成果:
- 纳入了15项人口药理动力学研究,涵盖了早产新生儿,儿童,孕妇/非孕妇和成年人.
- 在所有人群中,体重显著影响着阿齐思罗米辛的清除率和分布量.
- 清除受到儿童的年龄和肝功能的影响,以及女性的怀孕,非非洲血统和口服避孕药的使用.
结论:
- 目前的阿齐思罗米辛剂量取决于体重,但对于儿童和妇女来说,需要额外的预测因子来实现个性化治疗.
- 进一步研究阿兹罗米辛的剂量-暴露-反应关系对于精确的剂量调整和改善治疗结果至关重要.
更多相关视频
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
相关概念视频
Analysis of Population Pharmacokinetic Data
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
Mechanistic Models: Compartment Models in Individual and Population Analysis
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
